

## Faculty:

**Mark Flannagan**  
Chief Executive  
Beating Bowel Cancer

**Brian Gavin**  
Market Access and Government Affairs Consultant for the ROI  
MAP BioPharma Limited

**Mark Harries**  
Director  
MAP BioPharma Limited

**Christian Hill**  
Managing Director  
MAP BioPharma Limited

**Dawn Hill**  
Director  
MAP BioPharma Limited

**Lord Andrew Lansley**  
Member of the House of Lords  
UK Parliament

**Eric Low**  
CEO  
Myeloma UK

**Chris Mockler**  
Former Special Advisor to Ministers  
MAP BioPharma Limited

**Jennifer Prescott**  
Associate Director – Planning and Operations  
NICE

**Andy Rawson**  
Country Manager  
Dompé Pharmaceuticals

**Stuart Saw**  
Director of Financial Strategy  
NHS England

**Andrew Walker**  
Director  
Salus Alba



Conference organisers  
[www.cfsevents.co.uk](http://www.cfsevents.co.uk)



## Market Access for Life Sciences: Fact vs Fiction in 2017

**Friday 16<sup>th</sup> September 2016**

Royal College of Obstetricians and Gynaecologists,  
27 Sussex Place, London, NW1 4RG

To register please go to:

[www.cfsevents.co.uk/map-biopharma-conference](http://www.cfsevents.co.uk/map-biopharma-conference)  
or  
[www.mapbiopharma.com/map-conference](http://www.mapbiopharma.com/map-conference)

## Programme

For further information please email:

[Kirsty@cfsevents.co.uk](mailto:Kirsty@cfsevents.co.uk) or telephone: +44 (0)1438 751519



# Programme:

<b>09:45 – 10:30</b>	<b>Registration, Tea and Coffee</b>	<b>13:00 – 14:00</b>	<b>Lunch</b>
<b>10:30 – 10:45</b>	<b>Welcome and Introduction</b> Chairs: Dawn Hill and Mark Harries	<b>14:00 – 14:20</b>	<b>Perspectives Based on Working with Industry and Decision Makers to develop Trial Evidence through a ground-breaking Clinical Trials Network</b> Eric Low
<b>10:45 – 11:05</b>	<b>Key Note Lecture:</b> <b>Evolution of Health Policy and its Implications</b> Lord Andrew Lansley	<b>14:20 – 14:40</b>	<b>How to Make the Most of MAP</b> Andy Rawson
<b>11:05 – 11:25</b>	<b>Brexit Panel Discussion</b> Chris Mockler	<b>14:40 – 15:00</b>	<b>Legal Solutions to Market Access Barriers</b> Christian Hill
<b>11:25 – 11:45</b>	<b>Lessons Learned from the Dos and Don'ts of Working with Patient Advocacy Groups and the Life Sciences Industry</b> Mark Flannagan	<b>15:00 – 15:20</b>	<b>The New IPHA Agreement and Implications for 2017</b> Brian Gavin
<b>11:45 – 12:05</b>	<b>Evolution of NICE and Topic Selection of Specialised Medicines</b> Jenniffer Prescott	<b>15:20 – 15:40</b>	<b>NHS England Evolution, Critical Success Factors for 2017</b> Stuart Saw
<b>12:05 – 12:25</b>	<b>Scotland: How to Achieve Market Access in the Context of the Montgomery Review</b> Andrew Walker	<b>15:40 – 16:00</b>	<b>General Panel Discussion: Reflections on the Day</b>
<b>12:25 – 13:00</b>	<b>General Discussion, Q&amp;A session</b>	<b>16:00</b>	<b>Summary &amp; Close, Tea, Coffee and Networking</b>